Hypolipidemic and body fat-lowering effects of Fatclean in rats fed a high-fat diet.

The body fat-lowering and hypolipidemic effects of a Fatclean formula were examined in Sprague-Dawley rats fed a high-fat diet. Animals were given a normal control (NC) diet or a 15% high-fat (HF) diet with or without Fatclean (5%, wt/wt) supplement for 6 weeks. Fatclean formula contained phenolic compounds (14.3mg/g) and other functional compounds. Fatclean formula significantly lowered final body weights and visceral fat-pads weights, plasma total cholesterol (TC) and triglyceride (TG) concentrations, hepatic cholesterol and triglyceride levels, and hepatic hydroxyl-3-methylglutaryl-coenzyme A reductase (HMG-CoA) and acyl-coenzyme A:cholesterol acyltransferase (ACAT) activities compared to the HF group. Furthermore, adipocytic lipoprotein lipase (LPL) activity was also significantly elevated in the Fatclean group than in the HF group. The high-density lipoprotein-cholesterol/total-cholesterol (HDL-C/Total-C) ratio and atherogenic index (AI) were significantly improved in the Fatclean group than in the HF group. The accumulation of hepatic lipid droplets and the epididymal white adipocyte size were diminished in the Fatclean group than in the HF group. Accordingly, Fatclean seemed to be beneficial for the reduction of body weight and/or body fat and its hyperlipidemic property was highly active for enhancing the plasma lipids profile.

Anti-obesity and hypolipidemic effects of a proprietary herb and fiber combination (S&S PWH) in rats fed high-fat diets.

The objective of this study was to investigate the effects of S&S PWH, a proprietary herb and fiber combination (Bionutrigen Inc., Daejon, Republic of Korea), on body weight and lipid metabolism in rats fed with a high-fat diet. Three groups of male Sprague-Dawley rats were fed different diets for a 6-week period: normal control diet containing 5% (wt/wt) corn oil (NC group), high-fat diet containing 10% (wt/wt) lard plus 5% (wt/wt) corn oil (HF group), and high-fat diet supplemented with powdered 5% (wt/wt) S&S PWH (S&S PWH group). The body weights and relative weights of the epididymal and perirenal white adipose tissue were significantly lower in the S&S PWH group than in the HF group. S&S PWH supplementation significantly lowered plasma total cholesterol and triglyceride concentrations, whereas it elevated the ratio of high density lipoprotein-cholesterol/total-cholesterol and improved the atherogenic index. The accumulation of hepatic lipid droplets and the epididymal white adipocyte size were less in the S&S PWH group than in the HF group. Hepatic hydroxyl-3-methylglutaryl-coenzyme A reductase and acyl-coenzyme A:cholesterol acyltransferase activities were significantly lower, while adipocyte lipoprotein lipase activity was significantly higher, in the S&S PWH group than in the HF group. These beneficial effects may be due to the combined properties of the phenolic compounds present in high concentrations (1.89 g/100 g) in the S&S PWH. In conclusion, these results suggest that S&S PWH can be considered as an anti-obesity functional formula that is effective for suppressing body weight gain and enhancing lipid profile.

Hypocholesterolemic and antioxidant properties of 3-(4-hydroxyl)propanoic acid derivatives in high-cholesterol fed rats.

The purpose of the present study was to evaluate the in vivo efficacy of two cinnamic acid synthetic derivatives (allyl 3-[4-hydroxyphenyl]propanoate; HPP304, 1-naphthyl-methyl 3-[4-hydroxyphenyl]propanoate; HPP305) in high-cholesterol fed rats and compare their actions to that of cinnamic acid. Cinnamic acid and its synthetic derivatives were supplemented with a high-cholesterol diet for 42 days at a dose of 0.135 mmol/100g of diet. The supplementation of HPP304 and HPP305 significantly lowered cholesterol and triglyceride levels in the plasma and liver with a simultaneous increase in the HDL-cholesterol concentration, whereas cinnamic acid only lowered the plasma cholesterol concentration. Cinnamic acid lowered hepatic HMG-CoA reductase activity in high-cholesterol fed rats, however, its synthetic derivatives (HPP304 and HPP305) did not affect HMG-CoA reductase activity compared to the control group. Instead, the HPP304 and HPP305 supplements significantly lowered hepatic acyl coenzyme A:cholesterol acyltransferase activity and increased the fecal bile acid. The SOD activity of the erythrocytes and liver was not different between the groups, however, the activities of CAT and GSH-Px, and the level of GSH in the erythrocytes were significantly higher in the HPP304 and HPP305 groups than in the control group. On the other hand, the activities of CAT and GSH-Px, and the level of malondialdehyde in the liver were significantly lower in the HPP304 and HPP305 groups. The antioxidant activities of these cinnamic acid synthetic derivatives were similar to the cinnamic acid in the high-cholesterol fed rats. In addition, HPP304 and HPP305 lowered amniotransferase activity in the plasma. These results suggest that two cinnamic acid synthetic derivatives (HPP304 and HPP305) exert lipid-lowering action and antioxidant properties without hepatotoxicity in high-cholesterol fed rats.

Anticholesterolemic effect of 3,4-di(OH)-phenylpropionic amides in high-cholesterol fed rats.

Two amide synthetic derivatives of 3,4-di(OH)-hydrocinnamate (HC), 3,4-dihydroxyphenylpropionic (l-serine methyl ester) amide (E030) and 3,4-dihydroxyphenylpropionic (l-aspartic acid) amide (E076), were investigated to compare their lipid-lowering efficacy with HC. Male rats were fed a 1 g/100 g high-cholesterol diet for 6 weeks with supplements of either clofibrate (0.02%, w/w), HC (0.025%, w/w), E030 (0.039%, w/w) or E076 (0.041%, w/w). The clofibrate supplement was used as a positive control for the lipid-lowering efficacy. The food intakes and body weight gains were not significantly different among the groups. The plasma and hepatic cholesterol and triglyceride levels were lower in clofibrate, HC, E030, and E076-supplemented groups compared to the control group. The supplementation of HC and its amide derivatives was as effective as clofibrate in increasing the ratio of HDL-cholesterol to total plasma cholesterol and reducing the atherogenic index (AI). The hepatic cholesterol level in the HC and E076 groups was significantly lower than that in the clofibrate group. The hepatic 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA reductase) and acyl-CoA:cholesterol acyltransferase (ACAT) activities were significantly lower in the all test groups than in the control group. The excretion of neutral sterol was significantly higher in the HC, E030, and E076-supplemented groups compared to the control group. The plasma AST and ALT activities, indirect indexes of hepatic toxicity, were significantly lower in the HC, E030, and E076-supplemented groups than in the control group. Accordingly, the current results suggest that E030 and E076, two amide synthetic derivatives of HC, are effective in lowering lipid activity.

Effect of 3,4-di(OH)-cinnamate synthetic derivative on plasma and hepatic cholesterol level and antioxidant enzyme activities in high cholesterol-fed rats.

The effect of 3,4-di(OH)-phenylpropionic acid (L-phenylalanine methyl ester) amide (SL-1063), a synthetic derivative of 3,4-di(OH)-cinnamate, on the cholesterol metabolism and antioxidant enzyme system was examined in rats. Diets that included either SL-1063 (0.046%, w/w) or lovastatin (0.02%, w/w) as a supplement, plus 1 g cholesterol/100 g diet were fed to rats ad libitum for 5 weeks. The total plasma cholesterol and triglyceride levels were significantly lowered by the SL-1063 supplement compared to the control group. Meanwhile, the levels of plasma HDL-cholesterol and ratio of HDL-cholesterol/total cholesterol (%) were significantly higher in the SL-1063 group than in the control group. However, the lovastatin supplement did not affect the plasma lipid level. The hepatic cholesterol level and 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase activity were significantly lowered in the lovastatin group compared to the SL-1063 group; however, the hepatic triglyceride level did not differ among the groups. The activity of hepatic acyl CoA: cholesterol acyltransferase (ACAT), the enzyme that catalyzes hepatic cholesterol esterification, was significantly lower in the lovastatin and SL-1063 groups than in the control group. Furthermore, the SL-1063 supplement elevated the excretion of fecal sterols. As regards the hepatic antioxidant enzyme system, the superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), and glutathione reductase (GR) activities were all significantly higher in the SL-1063 group compared to the control group, whereas only the GR activity was significantly increased by the lovastatin supplement. No marked difference in the GSH levels and glucose-6-phosphate dehydrogenase (G6PD) activities was observed among the groups. The levels of plasma and hepatic thiobarbituric acid reactive substances (TBARS) were lowered by the SL-1063 supplement compared to the control group. Accordingly, the current results suggest that SL-1063, a synthetic derivative of 3,4-di(OH)-cinnamate, is effective in lowering the plasma lipids and improving the antioxidant enzyme system.

Saucernetin-7 and saucernetin-8 isolated from Saururus chinensis inhibit the LPS-induced production of nitric oxide and prostaglandin E2 in macrophage RAW264.7 cells.

In the present study, we demonstrate that saucernetin-8 ( 1) and saucernetin-7 ( 2), isolated from the underground parts of Saururus chinensis (Saururaceae), exerted potent inhibitory effects on LPS-induced nitric oxide (NO) and prostaglandin E (2) (PGE (2)) production in RAW 264.7 cells. Both compounds 1 and 2, known as dineolignans, also suppressed the expression of iNOS and COX-2 protein in a dose-dependent manner. Thus, this study suggests that compounds 1 and 2-mediated inhibition of iNOS and COX-2 expression may be one of the mechanisms responsible for the anti-inflammatory effects of the underground parts of Saururus chinensis.

Two cinnamate derivatives produce similar alteration in mRNA expression and activity of antioxidant enzymes in rats.

Cinnamate is a widespread secondary metabolite of phenolic compound synthesized by plants for defensive purposes. The current study was designed to investigate the effect of two structurally related cinnamate derivatives, 4-hydroxycinnamate and 3-(4-hydroxyphenyl)propionic acid (HPP), on the mRNA expression and activity of antioxidant enzymes in high-cholesterol-fed rats. Male rats were fed a 1 g/100 g high-cholesterol diet with supplements of either 4-hydroxycinnamate or HPP (0.135 mmol/100 g diet) for 6 weeks. The plasma paraoxonase activity was found to be higher in the cinnamate-derivative-supplemented groups than in the control group. The erythrocyte superoxide dismutase (SOD) and catalase (CAT) activities, plus glutathione (GSH) level, were all significantly higher in the 4-hydroxycinnamate- and HPP-supplemented groups than in the control group. However, both 4-hydroxycinnamate and HPP supplementation significantly lowered the hepatic activities and mRNA expression of CAT and glutathione peroxidase (GSH-Px) compared to the control group. The hepatic mRNA expression and activity of SOD did not differ between the groups. The hepatic thiobarbituric acid reactive substances (TBARS) level was significantly lowered by the 4-hydroxycinnamate and HPP supplementation. Accordingly, these results indicate that supplementation by 4-hydroxycinnamate and HPP would seem to enhance the antioxidative defense of erythrocyte. Both HPP and 4-hydroxycinnamate would appear to be beneficial in improving the function of antioxidative enzymes on a molecular level in high-cholesterol-fed rats.

4-hydroxycinnamate lowers plasma and hepatic lipids without changing antioxidant enzyme activities.

BACKGROUND/AIMS: The purpose of this study was to investigate the influence of 4-hydroxycinnamate (4-(OH)-C) supplement on the lipid metabolism and antioxidant system of rats fed a high-cholesterol diet. METHODS: Three groups of rats were given a diet containing 1 g cholesterol/kg for 6 weeks. The control group only received a high cholesterol diet, whereas the other two groups received a diet including lovastatin or 4-(OH)-C (0.1 g/100 g). RESULTS: The plasma total cholesterol concentration was significantly lowered by the 4-(OH)-C supplement, whereas the HDL-cholesterol level was higher in this group. The 4-(OH)-C supplement significantly lowered the hepatic cholesterol and triglycerides levels, respectively. Accumulation of hepatic lipid droplet was the highest in control group; however, it was decreased by supplementation of the 4-(OH)-C and the lovastatin. The hepatic HMG-CoA reductase activities were not significantly different between the groups, whereas the ACAT activity was significantly lowered in the lovastatin group. The 4-(OH)-C significantly lowered the hepatic TBARS content. And it did not alter the neutral sterol and total fecal sterol, however, the fecal acidic sterol was higher in the lovastatin and the 4-(OH)-C groups than in the control group. CONCLUSION: These results indicate that 4-(OH)-C was effective in lowering the plasma cholesterol and hepatic lipids.

Supplementation of naringenin and its synthetic derivative alters antioxidant enzyme activities of erythrocyte and liver in high cholesterol-fed rats.

The antioxidative effects of naringenin (1) and its synthetic derivative, naringenin 7-O-cetyl ether (2), were tested. Male rats were fed a 1 g/100 g high-cholesterol diet for 6 weeks with supplements of either 1 or 2 (0.073 mmol/100 g diet) to study the effects on the antioxidant enzyme activities in the erythrocyte and liver. The erythrocyte catalase (CAT) and superoxide dismutase (SOD) activities were significantly higher in the compounds 1 or 2 supplemented groups than in the control group, whereas the hepatic SOD and CAT activities were significantly lower in the compound 2 supplemented group. The compounds 1 and 2 supplements to a high cholesterol diet lowered or tended to lower the plasma TBARS levels, that is, lipid peroxide products, while enhancing the plasma paraoxonase activity. These results indicate that the supplementation of 1 and 2 was effective in improving the antioxidant capacity of the erythrocyte and liver, plus the synthetic functional compound 2 appeared to be as potent as 1 in enhancing the antioxidant defense system.

Comparison of antioxidant effects of naringin and probucol in cholesterol-fed rabbits.

BACKGROUND: Due to the strong evidence on the involvement of active oxygen species in a variety of disorders, the role of antioxidants against oxidative stress has recently received increased attention. METHODS: Twenty male rabbits were served a high-cholesterol (HC, 5 g/kg diet) diet or high-cholesterol diet supplemented with naringin (0.5 g/kg diet) or probucol (0.5 g/kg diet) for 8 weeks to compare the antioxidative effects of the citrus bioflavonoid (naringin) and antioxidative cholesterol-lowering drug (probucol). RESULTS: The plasma thiobarbituric acid-reactive substances (TBARS) concentration was not significantly different between the groups, whereas the hepatic TBARS concentration was significantly lower in the probucol group than in both normal and HC control or naringin group. Probucol and naringin supplementation led to an increase in the hepatic superoxide dismutase (SOD) and catalase (CAT) activities, and a decrease in the hepatic mitochondrial hydrogen peroxide (H(2)O(2)) content compared to the HC-control group. However, there was no difference in the cytosolic H(2)O(2) content or cytosolic glutathion peroxidase (GSH-Px) activity in the liver between the groups. Both naringin and probucol supplements significantly increased the plasma vitamin E concentration compared to the HC-control group. As regards the antioxidant enzyme gene expressions, naringin significantly increased the expression of three antioxidant enzyme mRNAs compared to the HC-control group, whereas probucol significantly increased the only SOD mRNA expression. CONCLUSIONS: The probucol supplement was very potent in the antioxidative defense system, whereas naringin exhibited a comparable antioxidant capacity based on increasing the gene expressions in the antioxidant enzymes, while also increasing the hepatic SOD and CAT activities, sparing plasma vitamin E, and decreasing the hepatic mitochondrial H(2)O(2) content.